(AGENPARL) - Roma, 23 Agosto 2024 - (AGENPARL) – ven 23 agosto 2024 Lund, Sweden, 23 August 2024. Hansa Biopharma AB, (“Hansa” or the “Company”)
(Nasdaq Stockholm: HNSA), today announced that Matthew Shaulis, Chief Commercial
Officer and US President has decided to leave the company in late September.
Effective immediately, the Commercial Leadership team will report to Søren
Tulstrup, President and CEO. A search is underway for a new CCO and US
President.
Matthew Shaulis, CCO and US President, Hansa Biopharma said, “Joining Hansa was
a key moment for my career and while the decision to leave was hard, especially
given the company’s solid progress, I know that the company will continue to
advance innovative science, deliver on its commitment to develop and launch
transformative new products, and help patients with rare immunological diseases.
I’m proud of the work we have done together at Hansa.”
Søren Tulstrup, President and CEO, Hansa Biopharma remarked, “Matt has been a
fantastic addition to the Hansa executive team and has made significant
contributions across the organization over the past years. I want to thank Matt
for his commitment and dedication to advancing key priorities including
commercialization efforts in Europe, acceleration of our ConfIdeS US pivotal
study, and the initiation of launch planning in the US, and we wish him well in
his new endeavor.
— ENDS —
Contacts for more information:
Evan Ballantyne, Chief Financial Officer
Stephanie Kenney, VP Global Corporate Affairs
Notes to editors
About Hansa Biopharma
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a
mission to develop and commercialize innovative, lifesaving and life-altering
treatments for patients with rare immunological conditions. Hansa Biopharma has
developed a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme
therapy, which has been shown to enable kidney transplantation in highly
sensitized patients. Hansa Biopharma has a rich and expanding research and
development program based on the Company’s proprietary IgG-cleaving enzyme
technology platform, to address serious unmet medical needs in transplantation,
autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund,
Sweden, and has operations in Europe and the U.S. The company is listed on
Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com
and follow us on LinkedIn (https://www.linkedin.com/company/hansa-medical-ab/).
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/3UDtp2sPHBaqz48FDDzGN3WZXeV6SP3fD4XtsNK6NSsYzzDGpcmPwQgxLRAYtdpwC9kEk41brEjPhGeYUkn8GHNqofgvpZQQKfgrhNiHQkUSyD.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
————————————————————
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
If you would rather not receive future communications from Hansa Biopharma AB, please go to https://optout.ne.cision.com/en/3UDtp2sPHBaqz48FDDzGN3WZXeV6SP3fD4XtsNK6NSsYzzDGpcmPwQgxLRAYtdpwC9kEk41brEjPhGeYUkn8GHNqofgvpZQQKfgrhNiHQkUSyD.
Hansa Biopharma AB, Scheelevägen 22, Lund, 22362 Sweden
Report this content
Trending
- Giornata internazionale dei diritti dell’infanzia e dell’adolescenza – INVITO STAMPA
- Stati Uniti, blackout nella rete segreta della NSA: comunicazioni classificate compromesse per il terzo giorno consecutivo
- Sbarco: Umberto Galimberti a “Fare memoria per costruire la pace
- Comunicato stampa: “La cura che connette”: il 3 dicembre un convegno all’Ospedale di Treviglio per la Giornata internazionale delle persone con disabilità
- Corso di formazione per gli addetti alla preparazione degli alimenti nella ristorazione pubblica
- RICORDIAMO OGGI IN PRESIDENZA E IN FIERA DEL LEVANTE
- SAISON CULTURELLE 2026/2027 – Musica, comicità e opera lirica: i prossimi appuntamenti della sezione Spectacle della Saison Culturelle 2026/2027
- L’abete di Terranova del Pollino in piazza San Pietro
- News Release – City of Toronto ushers in the 2026-2030 Toronto City Council term
- Agenzia nr. 2187 – Insediamento nuovo Procuratore Aggiunto a Brindisi. Caroli: ‘Ampia disponibilità e massima sinergia con la Commissione